Parvovirus B19 at the culprit coronary stenosis predicts outcome after stenting

Parvovirus (PV) B19 DNA is detected in endothelial cells and may cause endothelial dysfunction, which is involved in in‐stent restenosis. We aimed at performing an exploratory analysis that evaluated if PVB19 DNA at the culprit coronary stenosis would be associated with an increased rate of major adverse cardiac events (MACE) after coronary stenting.

[1]  K. Kent,et al.  Clinical Outcomes and Treatment After Drug-Eluting Stent Failure: The Absence of Traditional Risk Factors for In-Stent Restenosis , 2012, Circulation. Cardiovascular interventions.

[2]  G. Niccoli,et al.  The evolving role of inflammatory biomarkers in risk assessment after stent implantation. , 2010, Journal of the American College of Cardiology.

[3]  J. Towbin,et al.  Viral endomyocardial infection is an independent predictor and potentially treatable risk factor for graft loss and coronary vasculopathy in pediatric cardiac transplant recipients. , 2010, Journal of the American College of Cardiology.

[4]  J. Lefrère,et al.  Advances in Human B19 Erythrovirus Biology , 2010, Journal of Virology.

[5]  C. Tschöpe,et al.  Interferon beta modulates endothelial damage in patients with cardiac persistence of human parvovirus b19 infection. , 2010, The Journal of infectious diseases.

[6]  D. Moher,et al.  A catalogue of reporting guidelines for health research , 2010, European journal of clinical investigation.

[7]  K. Matschke,et al.  Prevalence of parvovirus B19 and human bocavirus DNA in the heart of patients with no evidence of dilated cardiomyopathy or myocarditis. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  Y. Tseng,et al.  Human parvovirus b19 infection in patients with coronary atherosclerosis. , 2009, Archives of medical research.

[9]  M. Cheitlin.  Coronary vasospasm as the underlying cause for chest pain in patients with PVB19 myocarditis , 2009 .

[10]  V. de Giorgi,et al.  Tissue persistence of parvovirus B19 genotypes in asymptomatic persons , 2008, Journal of medical virology.

[11]  W. Poller,et al.  Prevalence of erythrovirus genotypes in the myocardium of patients with dilated cardiomyopathy , 2008, Journal of medical virology.

[12]  K. Klingel,et al.  Coronary vasospasm as the underlying cause for chest pain in patients with PVB19 myocarditis , 2008, Heart.

[13]  S. Glynn,et al.  Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay , 2007, Transfusion.

[14]  K. Klingel,et al.  Presentation, Patterns of Myocardial Damage, and Clinical Course of Viral Myocarditis , 2006, Circulation.

[15]  F. Lang,et al.  Phospholipase A2 Activity-Dependent Stimulation of Ca2+ Entry by Human Parvovirus B19 Capsid Protein VP1 , 2006, Journal of Virology.

[16]  G. Montalescot,et al.  Correlation between Chlamydia pneumoniae detection from coronary angioplasty balloons and atherosclerosis severity. , 2006, Journal of the American College of Cardiology.

[17]  Patrick W Serruys,et al.  Coronary-artery stents. , 2006, The New England journal of medicine.

[18]  H. Schultheiss,et al.  Differential Aspects of Endothelial Function of the Coronary Microcirculation Considering Myocardial Virus Persistence, Endothelial Activation, and Myocardial Leukocyte Infiltrates , 2005, Circulation.

[19]  A. Lerman.  Restenosis: another "dysfunction" of the endothelium. , 2005, Circulation.

[20]  F. Bonvicini,et al.  Calibrated real-time PCR for evaluation of parvovirus b19 viral load. , 2004, Clinical chemistry.

[21]  H. Schultheiss,et al.  Endothelium-Dependent Flow-Mediated Vasodilation of Systemic Arteries Is Impaired in Patients With Myocardial Virus Persistence , 2003, Circulation.

[22]  B. Burke,et al.  Cytokine gene polymorphisms associated with symptomatic parvovirus B19 infection , 2003, Journal of clinical pathology.

[23]  K. Klingel,et al.  Parvovirus B19 Infection Mimicking Acute Myocardial Infarction , 2003, Circulation.

[24]  B. Maisch,et al.  Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens. , 2003, Human pathology.

[25]  K. Klingel,et al.  Fatal parvovirus B19-associated myocarditis clinically mimicking ischemic heart disease: an endothelial cell-mediated disease. , 2003, Human pathology.

[26]  L. Mitchell.  Parvovirus B19 nonstructural (NS1) protein as a transactivator of interleukin‐6 synthesis: Common pathway in inflammatory sequelae of human parvovirus infections? , 2002, Journal of medical virology.

[27]  K. Klingel,et al.  Parvovirus B19: a pathogen responsible for more than hematologic disorders , 2002, Virchows Archiv.

[28]  W. Koch.  Fifth (human parvovirus) and sixth (herpesvirus 6) diseases , 2001, Current opinion in infectious diseases.

[29]  J. Towbin,et al.  Association of viral genome with graft loss in children after cardiac transplantation. , 2001, The New England journal of medicine.

[30]  I. Vassias,et al.  Possible Interactions between the NS-1 Protein and Tumor Necrosis Factor Alpha Pathways in Erythroid Cell Apoptosis Induced by Human Parvovirus B19 , 1999, Journal of Virology.

[31]  T. Pumarola.  Parvovirus B19 , 1999, Transfusion Medicine and Hemotherapy.

[32]  F. Loop,et al.  Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). , 1988, Circulation.